Posted by Michael Wonder on 25 Aug 2024
FDA grants fast track designation to Aveta Biomics’ drug APG-157 for neo-adjuvant treatment of head and neck cancer
22 August 2024 - Aveta Biomics is pleased to announce that the US FDA has granted fast track designation to APG-157, its next-generation immuno-oncology drug, for the neo-adjuvant treatment of head and neck cancer.
APG-157 is a first in class drug that acts through a dual mechanism: inducing selective apoptosis of cancer cells while also reprogramming the immune environment.
